missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ LILRA2 Polyclonal Antibody

Description
Immunogen sequence: GHLPKPTLWA EPGSVIIQGS PVTLRCQGSL QAEEYHLYRE NKSASWVRRI QEPGKNGQFP IPSITWEHAG RYHCQYYSHN HSSEYSDPLE LVVTGAYSKP TLSALPSPVV TSGGNVTLQC VSQVAFDGFI LCKEGEDEHP QRLNSHSHAR GWSWAIFSVG PVSPSRRWSY RCYAYDSNSP YVWSLPSDLL ELLVPGVSKK PSLSVQPGPM VAPGESL.
Leukocyte Ig-like receptors (LIRs) are a family of immunoreceptors expressed predominantly on monocytes and B cells and at lower levels on dendritic cells and natural killer (NK) cells. All LIRs in subfamily B have an inhibitory function (LILRB1; MIM 604811). LIRs in subfamily A, with short cytoplasmic domains lacking an immunoreceptor tyrosine-based inhibitory motif (ITIM) and with trans membrane regions containing a charged arginine residue, may initiate stimulatory cascades. One member of subfamily A (LILRA3; MIM 604818) lacks a transmembrane region and is presumed to be a soluble receptor.
Specifications
Specifications
| Antigen | LILRA2 |
| Applications | ELISA, Western Blot |
| Classification | Polyclonal |
| Concentration | 2.83 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol and 0.02% sodium azide; pH 7.3 |
| Gene | LILRA2 |
| Gene Accession No. | Q8N149 |
| Gene Alias | CD85 antigen-like family member H; CD85h; ILT1; ILT-1; Immunoglobulin-like transcript 1; leucocyte Ig-like receptor A2; leukocyte immunoglobulin like receptor A2; leukocyte immunoglobulin-like receptor 7; Leukocyte immunoglobulin-like receptor subfamily A member 2; leukocyte immunoglobulin-like receptor subfamily A member 2 soluble; leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2; LILRA2; LIR7; LIR-7 |
| Gene Symbols | LILRA2 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?